Log in
Epilepsy, a condition that affects ca. 1% of the world's population, has severe clinical consequences; people with epilepsy (PWE) and poorly controlled seizures exhibit nearly an order of magnitude increase in premature death relative to the general population. About one-third of PWE do not benefit from treatment with currently approved medicines. Although historical evidence has suggested that cannabis might be useful in the control of epilepsy, work initiated by Drs Ben Whalley and Gary Stephens at University of Reading revealed that non-psychoactive components of cannabis can control epileptic seizures in animal models. This finding has led to a funded collaboration of ca £1.4M with GW Pharmaceuticals (UK) and Otsuka Pharmaceuticals (Japan) to establish a case for translation of two such components, cannabidiol (CBD) and cannabidavarin (CBDV), to human clinical drug trials. In particular, Reading research has resulted in GW trialling CBD (Phase 2, 50 participants, design stage) for a new indication of epilepsy treatment. A Phase 1 trial for CBDV (20 participants) began in July 2013, with a Phase 2 trial to begin immediately after successful completion of Phase 1. Results from the use of CBD on an open-label basis have shown major quality-of-life improvements for the patients concerned.
Research conducted by UEL's Drugs and Addictive Behaviours Research Group (DAB) and the UEL Institute for Research in Child Development (IRCD) from 1990-2012 has provided key information about the neuro-psychological risks of the use of the drug MDMA (Ecstasy).This information has been used by the US and UK governments, medical professionals and public information organisations. The research was included in the UK government Advisory Council on the Misuse of Drugs (ACMD, 2009) review of MDMA effects and informed government and public debate on the legal classification of MDMA. It has also supported associated debates around the potential harmful effects of MDMA. Subsequent media and public engagement with those debates has contributed to increased public awareness of the effects and risks of MDMA and engaged new audiences with important social and scientific issues. More recent research has informed parents and medical practitioners about the potential harmful effects of MDMA on specific aspects of infant functioning when taken during pregnancy.
Clare Stanford's group has opened up a new line of research for drug treatment of Attention Deficit Hyperactivity Disorder. Based on this work, UCL Business has been awarded an EU patent for the NK1R `knockout' mouse as an investigative tool and pharmaceutical screen. Cerebricon, a subsidiary of Charles River, has taken an exclusive licence to market this mouse and advertise it on their website. Our studies have also enabled us to identify a new genetic locus in which abnormalities are linked to ADHD in humans, and to identify a new drug candidate for treating ADHD.
Research into impaired cognitive performance related to drug misuse began at Edge Hill University (EHU) in 1998. It has predominantly concentrated upon impairments related to use of the illegal drug `ecstasy' (3,4-methylenedioxymethamphetamine: MDMA), although some has focussed upon cannabis related impairments in order to identify which of these drugs was related to a specific performance decrement. The impacts presented arise from contributions to policy development through the Advisory Council on the Misuse of Drugs (ACMD), the consultation response team of the British Psychological Society (BPS), media debate drawing upon our research, and through informing the design of a drug use prevention campaign.
Depression is a major public health problem producing substantial decrements in health and well-being, with 15% lifetime prevalence, affecting 350 million people worldwide. The Mood Disorders Centre (MDC) has improved treatment for depression by (i) understanding psychological mechanisms underpinning depression; (ii) translating this into innovative treatments and prevention interventions, evaluated in clinical trials; (iii) improving dissemination, delivery, and access to treatments. This research has improved patient care and quality of life, influenced national policy (NICE Depression Guidelines), informed national service and training provision (Improving Access to Psychological Therapies IAPT programme, with 680,000 people completing treatment 2008-2011) and achieved international impact on clinical practice.
The pioneering work undertaken at UCL has had a major impact on clinical practice for the treatment of self-harming, suicidal patients with a diagnosis of borderline personality disorder and the techniques have been drawn on in extensions to other common mental disorders including eating disorder, substance misuse, and antisocial personality disorder. This treatment, known as mentalisation based therapy or MBT, has since been applied in a range of clinical settings including inpatient and outpatient work in the UK and internationally. This case study presents two areas in particular where our research has been applied: the treatment of personality disorders, and in work with troubled adolescents.
There is strong evidence that Mindfulness-Based Cognitive Therapy (MBCT) plays a major role not only in preventing the recurrence of depression, but also in enhancing well-being more broadly. Much of this research was carried out at Bangor University's Centre for Mindfulness Research and Practice, with a focus on non-academic impact from the outset. Between 2008-2013, the Centre has delivered MBCT courses to over 1500 members of the public. We have also trained over 1300 professionals to deliver MBCT within the NHS and other contexts, leading to several successful spin-off businesses. Finally, Centre researchers lead in the creation of UK good practice standards.
Research by Professor Abdul Basit's group at the UCL School of Pharmacy is leading to improved treatments for ulcerative colitis and other conditions through increased knowledge of the complex physiology of the gastrointestinal tract. Improved understanding of in vivo drug release and uptake has allowed development of three patent-protected technologies for improved drug delivery: PHLORALTM, for release of drugs in the colon, and DuoCoatTM and ProReleaseTM formulations designed to allow intact transit through the stomach followed by immediate release upon gastric emptying. These technologies are the subject of licences and ongoing development programmes, with PHLORALTM currently in phase III clinical trials. The impact is therefore the introduction of enabling technologies that have positively influenced the drug development programmes of pharmaceutical companies.
Research into primary care insomnia by the Community and Health Research Unit (CaHRU) has led to broad improvements in healthcare provision for insomnia, improved patient quality of life, informed national/international policy and practice in insomnia care and impacted directly on health professional practice and insomnia sufferers, initially in Lincolnshire spreading across the UK and internationally from 2008 to 2011. Direct effects on practice include changes in sleep management and reduced hypnotic prescribing through seminars, workshops, conferences and e-learning developed by the team; inclusion in UK policy, practitioner information, training materials and guidance on hypnotics has led to greater professional and public awareness of sleep management internationally.
Dalgleish proposed a programme to develop thalidomide analogues for their immunomodulatory and anti-neoplastic actions. Working with a small start-up company, Celgene, several analogues including lenalidomide and pomalidomide were developed and entered clinical trials. Both drugs significantly prolong patient survival in myeloma and myelodysplasia and have received FDA and NICE approval for these purposes. Celgene has grown into a large multi-national company with over 5000 employees. Lenalidomide sales were $3.8 billion in 2012.